All In the pipeline articles – Page 7
-
OpinionBespoke or bodged
A can-do attitude and some lateral thinking can save time and money when it comes to exotic apparatus, says Derek Lowe
-
Opinion
From lab to leader
Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?
-
Opinion
New antibiotics: what's the hold up?
It’s more a research problem, than a commercial one, says Derek Lowe
-
OpinionName reactions: how does the label stick?
Derek Lowe investigates the long running tradition of naming reactions after their inventors
-
OpinionFear of the unknown
How do you reconcile the need for personal safety with unfamiliar compounds, asks Derek Lowe
-
OpinionFull disclosure?
The pharma industry should be more open with its trial data, says Derek Lowe
-
Opinion
High finance meets big pharma?
Derek Lowe examines an alternative funding model for pharmaceutical research
-
-
-
-
-
OpinionPeace, love and understanding
Chemists and biologists often view the process of drug discovery very differently
-
Opinion
Column: In the pipeline
Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
-
Opinion
Column: In the pipeline
Derek Lowe wonders what the lab lingua franca might be in the years to come
-
Opinion
Column: In the pipeline
Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
-
Opinion
Column: In the pipeline
Derek Lowe discusses the compounds you can buy but won't see anywhere in the literature
-
Opinion
Column: In the pipeline
You have to make space for good sense when thinking about safety, argues Derek Lowe